Publication:
Neoadjuvant intralesional methotrexate for juvenile xanthogranuloma in an adult.

No Thumbnail Available

Date

2021-11-07

Authors

Tomas-Velazquez, Alejandra
Reyes-Mugica, Miguel
Gonzalez-Menchen, Alberto
Estenaga, Angela
Antoñanzas, Javier
Morello-Vicente, Ana
Salido-Vallejo, Rafael

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Dear Editor, Juvenile xanthogranuloma (JXG) is a non-Langerhans cell histiocytosis usually occurring in infants and typically located in the head or neck. Clinically, solitary skin lesions are found in 60%–82% of patients, and the most common variant is characterized by one yellowish nodule. Adult onset is rare, and although JXG is usually self-limiting in children, spontaneous resolution is uncommon at older ages. In addition, up to 50% of patients with spontaneous regression develop an atrophy or anetodermal area. Thus, complete excision is frequently performed in this population subgroup to achieve better cosmetic results. In disseminated forms, different chemotherapy regimens, corticosteroids, and other systemic therapies are used. Herein, we report a case of adult JXG treated with intralesional methotrexate (MTX) resulting in a rapid reduction in size.

Description

MeSH Terms

Adult
Humans
Injections, Intralesional
Neoadjuvant Therapy
Keratoacanthoma

DeCS Terms

Remisión espontánea
Espectroscopía de resonancia por spin del electrón
Células de Langerhans
Neoplasias cutáneas
Úlcera cutánea

CIE Terms

Keywords

Xanthogranuloma, Juvenile, Methotrexate, Remission, Spontaneous

Citation

Tomás-Velázquez A, Reyes-Múgica M, González-Menchen A, Estenaga Á, Antoñanzas J, Morelló-Vicente A, et al. Neoadjuvant intralesional methotrexate for juvenile xanthogranuloma in an adult. Dermatol Ther. 2022 Jan;35(1):e15200